Active, not recruitingPhase 1NCT05698199

Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Immunomic Therapeutics, Inc.
Intervention
ITI-1001(drug)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05698199 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials